Linperlisib combination for newly diagnosed nodal T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, linperlisib, combined with standard chemotherapy (CHOP) for people newly diagnosed with a rare type of T-cell lymphoma (nTFHL) who plan to have a stem cell transplant. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of nodal T-follicular helper cell lymphoma (a specific type of T-cell lymphoma).
- You plan to receive a stem cell transplant using your own cells (autologous).
- You have not had any prior cancer treatment for this lymphoma.
- You have at least one lymph node larger than 1.5 cm or another tumor larger than 1 cm that can be measured.
- You are between 18 and 65 years old.
- You are well enough to perform daily activities (ECOG score 0-2) and expected to live at least 12 more weeks.
- Your bone marrow, kidney, liver, and blood counts are within acceptable ranges (details provided by your doctor).
- You can swallow pills and do not have chronic diarrhea or bowel blockage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
Hear when a new Nodal T-follicular Helper Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.